NCT06714916 Optimising Renal Tumour Management Through Artificial Intelligence Modules
| NCT ID | NCT06714916 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shao Pengfei |
| Condition | Renal Neoplasms |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,100 participants |
| Start Date | 2025-01-01 |
| Primary Completion | 2028-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,100 participants in total. It began in 2025-01-01 with a primary completion date of 2028-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to improve the management of people with renal tumour by multimodal artificial intelligence(AI). It will also measure the accuracy of the predictions from AI models. The main questions it aims to answer are: 1. whether the AI module can accurately provide tumor-related information such as Benign or malignant, subtypes, grading, stage, etc. by learning from preoperative CT images. 2. whether the AI module can help clinicians find out the most suitable surgical programme for people with renal tumor. 3. whether the AI module can integrate CT images and pathology slides, offering supplementary prognostic information to improve postoperative survival. Participants who complete a CT(usually Contrast-enhanced CT, CECT) examination and undergo radical or partial nephrectomy will carry out active surveillance and record postoperative survival data for 5 years.
Eligibility Criteria
Inclusion Criteria: * Patients with renal tumor which can be treated by surgery; * Complete CECT within 30 days before surgery; * Patients who fully understand this study and sign the informed consent; Exclusion Criteria: * Patients with any item missing from the baseline clinical and pathological information; * Patients who has already metastasized by the time the tumor is discovered; * Previous treatment in any form, including surgery, targeted therapy and immunotherapy;
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06714916 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Renal Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06714916 currently recruiting?
Yes, NCT06714916 is actively recruiting participants. Contact the research team at spf032@hotmail.com for enrollment information.
Where is the NCT06714916 trial being conducted?
This trial is being conducted at Nanjing, China.
Who is sponsoring the NCT06714916 clinical trial?
NCT06714916 is sponsored by Shao Pengfei. The trial plans to enroll 2,100 participants.